{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:45:40Z","timestamp":1794584740126,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016508","name":"bluebird bio","doi-asserted-by":"publisher","award":["bluebird bio"],"award-info":[{"award-number":["bluebird bio"]}],"id":[{"id":"10.13039\/100016508","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>X-linked adrenoleukodystrophy (ALD) is a rare metabolic and neurodegenerative disorder belonging to the group of leukodystrophies, with an estimated incidence around 1:25 000 newborns worldwide, mostly among men. Childhood Cerebral ALD (CCALD) is the most severe form with a poor prognosis if not properly treated during the first years of life. Currently, only allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely available for CCALD treatment. To date, there is a lack of data regarding CCALD epidemiology, natural history, and current management in France. This knowledge is crucial for the development of new therapies such as gene therapies. In this context, the French National Health Data System (SNDS) is a particularly indicated database to collect information meeting these needs. A non-interventional, national, real-life, retrospective study was performed using secondary data from the national ALD registry (LEUKOFRANCE) and SNDS. CCALD patients detected between 2009 and 2018 and successfully matched between LEUKOFRANCE and SNDS were included in this study. Index date was defined as the first CCALD event detected during study period. Subgroups of patients with sufficient follow-up (6 months) and history (1 year) available around index date were analyzed to assess CCALD burden and natural history.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>52 patients were included into the matched cohort. Median annual incidence of CCALD was estimated at 4 patients. Median age at CCALD diagnosis was 7.0 years. Among patients without allo-HSCT, five-year overall survival was 66.6%, with 93.3% of them presenting at least one CCALD symptom and 62.1% presenting a least one major functional disability (MFD). Among patients with allo-HSCT, five-year overall survival was 94.4%, with only 11.1% of patients presenting CCALD symptoms, and 16.7% of presenting a MFD. Mean annualized costs were almost twice as important among patients without allo-HSCT, with 49,211\u20ac, 23,117\u20ac, respectively. Costs were almost exclusively represented by hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To the best of our knowledge, this is the most up to date study analyzing CCALD epidemiology, clinical and economic burden in France. The necessity of a precocious management with HSCT highlight the potential benefits of including an expanded screening program among newborns, coupled with family screenings when a mutation is detected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-023-02843-x","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T09:02:11Z","timestamp":1691658131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Childhood cerebral adrenoleukodystrophy (CCALD) in France: epidemiology, natural history, and burden of disease - A population-based study"],"prefix":"10.1186","volume":"18","author":[{"given":"Caroline","family":"Sevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Hatteb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Bignami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Chillotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Bugnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e8ve","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Boespflug-Tanguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"2843_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/(SICI)1096-8628(19980413)76:5<420::AID-AJMG10>3.0.CO;2-O","volume":"76","author":"EP Kirk","year":"1998","unstructured":"Kirk EP, Fletcher JM, Sharp P, Carey B, Poulos A. X-linked adrenoleukodystrophy: the Australasian experience. Am J Med Genet. 1998;76:420\u20133.","journal-title":"Am J Med Genet"},{"key":"2843_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.101","volume":"49","author":"L Bezman","year":"2001","unstructured":"Bezman L, Moser AB, Raymond GV, Rinaldo P, Watkins PA, Smith KD, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol. 2001;49:512\u20137.","journal-title":"Ann Neurol"},{"key":"2843_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.braindev.2009.02.002","volume":"32","author":"LB Jardim","year":"2010","unstructured":"Jardim LB, da Silva ACF, Blank D, Villanueva MM, Renck L, Costa MLB, et al. X-linked adrenoleukodystrophy: clinical course and minimal incidence in South Brazil. Brain Dev. 2010;32:180\u201390.","journal-title":"Brain Dev"},{"key":"2843_CR4","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1210\/jc.2018-00920","volume":"103","author":"MO Regelmann","year":"2018","unstructured":"Regelmann MO, Kamboj MK, Miller BS, Nakamoto JM, Sarafoglou K, Shah S, et al. Adrenoleukodystrophy: Guidance for adrenal surveillance in males identified by newborn screen. J Clin Endocrinol Metab. 2018;103:4324\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"2843_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1750-1172-7-51","volume":"7","author":"M Engelen","year":"2012","unstructured":"Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7:51.","journal-title":"Orphanet J Rare Dis"},{"key":"2843_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ando.2007.04.002","volume":"68","author":"P Aubourg","year":"2007","unstructured":"Aubourg P. Adr\u00e9noleucodystrophie li\u00e9e \u00e0 l\u2019X. Ann Endocrinol. 2007;68:403\u201311.","journal-title":"Ann Endocrinol"},{"key":"2843_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/ncpneuro0421","volume":"3","author":"HW Moser","year":"2007","unstructured":"Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract Neurol. 2007;3:140\u201351.","journal-title":"Nat Clin Pract Neurol"},{"key":"2843_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","volume":"25","author":"GV Raymond","year":"2019","unstructured":"Raymond GV, Aubourg P, Paker A, Escolar M, Fischer A, Blanche S, et al. Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:538\u201348.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2843_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-2000-9236","volume":"31","author":"HW Moser","year":"2000","unstructured":"Moser HW, Loes DJ, Melhem ER, Raymond GV, Bezman L, Cox CS, et al. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics. 2000;31:227\u201339.","journal-title":"Neuropediatrics"},{"key":"2843_CR10","first-page":"1761","volume":"15","author":"DJ Loes","year":"1994","unstructured":"Loes DJ, Hite S, Moser H, Stillman AE, Shapiro E, Lockman L, et al. Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994;15:1761\u20136.","journal-title":"AJNR Am J Neuroradiol"},{"key":"2843_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1212\/WNL.0000000000201374","volume":"99","author":"M Engelen","year":"2022","unstructured":"Engelen M, van Ballegoij WJC, Mallack EJ, Van Haren KP, K\u00f6hler W, Salsano E, et al. International Recommendations for the diagnosis and management of patients with adrenoleukodystrophy: a Consensus-Based Approach. Neurology. 2022;99:940\u201351.","journal-title":"Neurology"},{"key":"2843_CR12","doi-asserted-by":"publisher","first-page":"e190081","DOI":"10.1001\/jamapediatrics.2019.0081","volume":"173","author":"SH Parikh","year":"2019","unstructured":"Parikh SH, Satwani P, Ahn KW, Sahr NA, Fretham C, Abraham AA, et al. Survival Trends in Infants undergoing allogeneic hematopoietic cell transplant. JAMA Pediatr. 2019;173:e190081.","journal-title":"JAMA Pediatr"},{"key":"2843_CR13","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","volume":"377","author":"F Eichler","year":"2017","unstructured":"Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med Massachusetts Medical Society. 2017;377:1630\u20138.","journal-title":"N Engl J Med Massachusetts Medical Society"},{"key":"2843_CR14","unstructured":"R\u00e9publique fran\u00e7aise. D\u00e9cret n\u00b0 2016 \u2013 1871 du 26 d\u00e9cembre 2016 relatif au traitement de donn\u00e9es \u00e0 caract\u00e8re personnel d\u00e9nomm\u00e9 \u00ab syst\u00e8me national des donn\u00e9es de sant\u00e9 \u00bb. 2016 \u2013 1871 Dec 26, 2016."},{"key":"2843_CR15","unstructured":"Syst\u00e8me National des Donn\u00e9es de Sant\u00e9. Qu\u2019est-ce que le SNDS ? | SNDS [Internet]. [cited 2021 Oct 20]. Available from: https:\/\/www.snds.gouv.fr\/SNDS\/Qu-est-ce-que-le-SNDS."},{"key":"2843_CR16","unstructured":"Direction de la S\u00e9curit\u00e9 Sociale. CHIFFRES CLES 2020 ED2019.pdf [Internet]. [cited 2021 Oct 20]. Available from: https:\/\/www.securite-sociale.fr\/files\/live\/sites\/SSFR\/files\/medias\/DSS\/2020\/CHIFFRES%20CLES%202020%20ED2019.pdf."},{"key":"2843_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","volume":"36","author":"G Moulis","year":"2015","unstructured":"Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J-L, Sailler L. French health insurance databases: what interest for medical research? Rev M\u00e9decine Interne. 2015;36:411\u20137.","journal-title":"Rev M\u00e9decine Interne"},{"key":"2843_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","volume":"58","author":"P Tuppin","year":"2010","unstructured":"Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merli\u00e8re Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58:286\u201390.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2843_CR19","unstructured":"World Health Organization. ICD-10 Version:2019 [Internet]. [cited 2021 Oct 20]. Available from: https:\/\/icd.who.int\/browse10\/2019\/en."},{"key":"2843_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12882-020-1692-4","volume":"21","author":"M Raffray","year":"2020","unstructured":"Raffray M, Bayat S, Lassalle M, Couchoud C. Linking disease registries and nationwide healthcare administrative databases: the french renal epidemiology and information network (REIN) insight. BMC Nephrol. 2020;21:25.","journal-title":"BMC Nephrol"},{"key":"2843_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3917\/spub.139.0355","volume":"26","author":"J Perlbarg","year":"2014","unstructured":"Perlbarg J, Allonier C, Boisnault P, Daniel F, Fur P, Szidon P, et al. Faisabilit\u00e9 et int\u00e9r\u00eat de l\u2019appariement de donn\u00e9es individuelles en m\u00e9decine g\u00e9n\u00e9rale et de donn\u00e9es de remboursement appliqu\u00e9 au diab\u00e8te et \u00e0 l\u2019hypertension art\u00e9rielle. Sant\u00e9 Publique. 2014;26:355.","journal-title":"Sant\u00e9 Publique"},{"key":"2843_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.acvd.2020.04.006","volume":"113","author":"R Didier","year":"2020","unstructured":"Didier R, Gouysse M, Eltchaninoff H, Le Breton H, Commeau P, Cayla G, et al. Successful linkage of french large-scale national registry populations to national reimbursement data: improved data completeness and minimized loss to follow-up. Arch Cardiovasc Dis. 2020;113:534\u201341.","journal-title":"Arch Cardiovasc Dis"},{"key":"2843_CR23","unstructured":"Caisse Nationale d\u2019Assurance Maladie. CCAM en ligne - CCAM [Internet]. [cited 2021 Jun 2]. Available from: https:\/\/www.ameli.fr\/accueil-de-la-ccam\/index.php."},{"key":"2843_CR24","unstructured":"Caisse Nationale d\u2019Assurance Maladie. Pr\u00e9sentation TNB [Internet]. [cited 2021 Oct 20]. Available from: http:\/\/www.codage.ext.cnamts.fr\/codif\/nabm\/index_presentation.php?p_site=AMELI."},{"key":"2843_CR25","unstructured":"Caisse Nationale d\u2019Assurance Maladie, Nomenclatures. NGAP et LPP [Internet]. [cited 2021 Sep 22]. Available from: https:\/\/www.ameli.fr\/infirmier\/exercice-liberal\/facturation-remuneration\/nomenclatures-ngap-lpp\/nomenclatures-ngap-lpp."},{"key":"2843_CR26","unstructured":"World Health Organization. WHOCC \u2013 ATC\/DDD Index [Internet]. [cited 2021 Jun 2]. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"2843_CR27","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9. Qu\u2019est-ce que le code CIP 13 et le Datamatrix ? [Internet]. [cited 2021 Oct 20]. Available from: https:\/\/solidarites-sante.gouv.fr\/soins-et-maladies\/medicaments\/professionnels-de-sante\/suppression-de-la-vignette-pharmaceutique-questions-reponses-a-l-attention-des\/article\/qu-est-ce-que-le-code-cip-13-et-le-datamatrix."},{"key":"2843_CR28","unstructured":"Insee. Institut national de la statistique et des \u00e9tudes \u00e9conomiques [Internet]. [cited 2021 Oct 20]. Available from: https:\/\/www.insee.fr\/fr\/accueil."},{"key":"2843_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jdn.10003","volume":"80","author":"BR Turk","year":"2020","unstructured":"Turk BR, Theda C, Fatemi A, Moser AB. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci Off J Int Soc Dev Neurosci. 2020;80:52\u201372.","journal-title":"Int J Dev Neurosci Off J Int Soc Dev Neurosci"},{"key":"2843_CR30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/jimd.12356","volume":"44","author":"EJ Mallack","year":"2021","unstructured":"Mallack EJ, Turk BR, Yan H, Price C, Demetres M, Moser AB, et al. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. J Inherit Metab Dis. 2021;44:728\u201339.","journal-title":"J Inherit Metab Dis"},{"key":"2843_CR31","doi-asserted-by":"publisher","first-page":"e180769","DOI":"10.1001\/jamanetworkopen.2018.0769","volume":"1","author":"J-S K\u00fchl","year":"2018","unstructured":"K\u00fchl J-S, Kupper J, Baqu\u00e9 H, Ebell W, G\u00e4rtner J, Korenke C, et al. Potential risks to stable long-term outcome of allogeneic hematopoietic stem cell transplantation for children with cerebral X-linked adrenoleukodystrophy. JAMA Netw Open. 2018;1:e180769.","journal-title":"JAMA Netw Open"},{"key":"2843_CR32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13023-018-0921-4","volume":"13","author":"A Bessey","year":"2018","unstructured":"Bessey A, Chilcott JB, Leaviss J, Sutton A. Economic impact of screening for X-linked adrenoleukodystrophy within a newborn blood spot screening programme. Orphanet J Rare Dis. 2018;13:179.","journal-title":"Orphanet J Rare Dis"},{"key":"2843_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5114\/pedm.2019.85821","volume":"25","author":"M Herman","year":"2019","unstructured":"Herman M, Jura M, Krakowska K, Barg E. X-linked adrenoleukodystrophy diagnosed in three brothers. Pediatr Endocrinol Diabetes Metab. 2019;25:95\u20138.","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"2843_CR34","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/j.1750-3639.2010.00394.x","volume":"20","author":"N Cartier","year":"2010","unstructured":"Cartier N, Aubourg P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-Linked adrenoleukodystrophy. Brain Pathol. 2010;20:857\u201362.","journal-title":"Brain Pathol"},{"key":"2843_CR35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:364\u201389.","journal-title":"J Clin Endocrinol Metab"},{"key":"2843_CR36","unstructured":"Kanakis G, Kaltsas G. Adrenal Insufficiency Due to X-Linked Adrenoleukodystrophy. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2021 Sep 23]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK278944\/."},{"key":"2843_CR37","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood-2011-01-329235","volume":"118","author":"WP Miller","year":"2011","unstructured":"Miller WP, Rothman SM, Nascene D, Kivisto T, DeFor TE, Ziegler RS, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood. 2011;118:1971\u20138.","journal-title":"Blood"},{"key":"2843_CR38","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1182\/blood-2003-10-3402","volume":"104","author":"C Peters","year":"2004","unstructured":"Peters C, Charnas LR, Tan Y, Ziegler RS, Shapiro EG, DeFor T, et al. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104:881\u20138.","journal-title":"Blood"},{"key":"2843_CR39","unstructured":"Mahmood et al. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17618834\/."},{"key":"2843_CR40","doi-asserted-by":"publisher","unstructured":"Carreras E, Dufour C, Mohty M, Kr\u00f6ger N, editors. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. Cham: Springer International Publishing; 2019 [cited 2021 Jul 22]. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-030-02278-5.","DOI":"10.1007\/978-3-030-02278-5"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02843-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02843-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T10:33:27Z","timestamp":1700390007000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02843-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2843"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02843-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are issued from the French National Health Insurance information system with agreement from the French National Data Protection Agency. The study protocol was approved on June 13, 2019, by the Expert Committee for Healthcare Data Research. During their inclusion in LEUKOFRANCE registry, patients or legal guardian signed a consent form for their data to be used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not concerned.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CS has no conflict of interest to be disclosed. SH has no conflict of interest to be disclosed. AC has been employed by bluebird bio during this study and until October 2021. FBi has been employed by bluebird bio during this study and until January 2022. LC and FBu are employees of st\u00e8ve consultants, which has a research consultancy contract with Bluebird Bio. SB is the executive director of st\u00e8ve consultants, which has a research consultancy contract with Bluebird Bio. OBT has no conflict of interest to be disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}